-- テラ・イノバタム・グローバル（NKLR）は水曜日、原子力燃料・合金メーカーのコニュアー社と提携契約を締結したと発表した。この提携は、同社のSOLO原子炉プラットフォームの規模拡大展開を支援するため、製造技術の向上を目指すものだ。 この契約は、原子炉炉心性能に不可欠な材料であるジルコニウム合金とステンレス鋼を用いた構造部品および機能部品の製造プロセスの開発と標準化に重点を置いている。 テラ社はまた、コニュアー社のジルコニウム合金製造に関する専門知識を活用し、建設可能性に関する研究を進める予定だと述べた。
Price: $5.85, Change: $-0.49, Percent Change: -7.73%
Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.95, Change: $-0.05, Percent Change: -0.11%
Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price by $8 to $196, 19x our 2026 EPS estimate (unchanged) and a discount to its 23x five-year average forward multiple, reflecting geopolitical risks. We lower our 2026 EPS to $10.33 from $10.74 and 2027's to $11.58 from $12.07, primarily reflecting lower gross bookings growth from the Middle East conflict. We maintain our Buy opinion as shares are undervalued given long-term competitive strengths and temporary geopolitical headwinds. The company's Connected Trip platform and Genius loyalty program are supporting higher-margin direct bookings, suggesting AI initiatives are strengthening consumer engagement rather than disintermediating the platform. Strong free cash flow supports future shareholder returns, including $3.6 billion in Q1 buybacks. While the Middle East conflict will impact Q2 bookings, BKNG has a history of seeing travel rebound following geopolitical or economic disruptions. U.S. room night growth accelerated in Q1 to a low-teens range, providing near-term momentum.